Omeros (OMER) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on June 27, 2025, with shareholders able to vote and submit questions online.

• Key business highlights include regulatory progress for narsoplimab, clinical advancements in complement inhibitors, and non-dilutive capital raised through royalty monetization and debt reduction.

• Shareholders of record as of May 23, 2025, are entitled to vote on all matters.

Voting matters and shareholder proposals

• Shareholders will vote to elect two Class I directors, approve an advisory resolution on executive compensation, and ratify Ernst & Young LLP as the independent auditor.

• Board recommends voting FOR all director nominees and proposals.

• Shareholder proposals for the 2026 meeting must be submitted by January 30, 2026.

Board of directors and corporate governance

• Board is divided into three classes with staggered terms; two Class I directors are up for election.

• Board leadership combines CEO and chairman roles, with a lead independent director providing oversight.

• Committees include audit, compensation, nominating and governance, and scientific, each with defined responsibilities.

• Board diversity is considered in director nominations, with two directors identified as diverse.

• No term limits or mandatory retirement age for directors.